Navigation Links
Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
Date:2/29/2008

HAYWARD, Calif., Feb. 29 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Gary S. Titus, Kosan's Senior Vice President and Chief Financial Officer, will present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference in New York at the W Hotel on Tuesday, March 4, 2008 at 10:30 a.m. EST. A live webcast of the presentation can be accessed through http://www.wsw.com/webcast/sig7/kosn/.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentations will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Kosan Announces Third Quarter 2007 Financial Results
7. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
8. Kosan Announces February 28, 2008 Conference Call and Webcast
9. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
10. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... 2016 , ... Kablooe Design, a leading provider of product design and development ... of the business. “We have worked hard to build long-term relationships,” says President and ... and honor of serving their product design and development needs through the years.” , ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in Ashland, ... building is complete. The new structure adds a third office building to the current ... purchased 2.4 acres of land, along with office space adjacent to the previous ...
(Date:5/19/2016)... ... May 19, 2016 , ... ... (CRO) has welcomed Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , ... vaccine and translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve ...
(Date:5/18/2016)... ... 18, 2016 , ... Tech Coast Angels (TCA) today announced that ... at the annual ACA Summit last week in Philadelphia. , The award ... member angel groups. It is the highest honor available for an early-stage company to ...
Breaking Biology Technology:
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), a company ... of a new series of commercials on Time Warner Cable ... .  The commercials will air on Bloomberg TV, Fox Business ... show. --> NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ...
(Date:3/11/2016)... March 11, 2016 http://www.apimages.com ) - ... Picture is available at AP Images ( http://www.apimages.com ) - ... be used to produce the new refugee identity cards. DERMALOG will ... at CeBIT in Hanover next week.   ... will be used to produce the new refugee identity cards. DERMALOG ...
Breaking Biology News(10 mins):